Generated by AI
Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infectious diseases. Its work centers on advancing innovative therapeutic candidates and related research tools that support discovery, preclinical development, and clinical development. Precigen also operates through business segments that include biopharmaceutical activities and specialized research-model services, giving it a broad presence across therapeutic development and life-science applications. Headquartered in Germantown, Maryland, Precigen serves as a clinical-stage innovator in the biotechnology sector, with an emphasis on translating proprietary technology platforms into potential treatments for patients with unmet medical needs.
Website20374 Seneca Meadows Parkway
Germantown, MD, 20876
United States
The latest articles about PGEN.
Precigen has the same combination that made Xeris work: a fast-growing product and a pipeline the market isn’t pricing in.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about PGEN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.